1. Home
  2. MTEK vs GDTC Comparison

MTEK vs GDTC Comparison

Compare MTEK & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.16

Market Cap

11.7M

Sector

N/A

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

N/A

Current Price

$1.17

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MTEK
GDTC
Founded
2008
2018
Country
Israel
Singapore
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MTEK
GDTC
Price
$1.16
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
351.5K
19.0K
Earning Date
05-12-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.68
52 Week High
$4.27
$3.68

Technical Indicators

Market Signals
Indicator
MTEK
GDTC
Relative Strength Index (RSI) 46.03 52.01
Support Level $1.08 $0.93
Resistance Level $1.44 $1.25
Average True Range (ATR) 0.13 0.09
MACD 0.01 -0.00
Stochastic Oscillator 38.46 3.46

Price Performance

Historical Comparison
MTEK
GDTC

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: